Anebulo Pharmaceuticals, Inc. Price & Performance (ANEB)

Anebulo Pharmaceuticals has regained compliance with Nasdaq listing requirements following recent board restructuring and a lock-up agreement with a major investor. The company had faced a deadline to resolve a control change issue, and its swift action has stabilized its market position, providing a foundation for future corporate moves.12

Anebulo Pharmaceuticals stock fell nearly 6% to $0.95, hitting the lower end of its recent trading range. Despite the decline, analysts maintain a buy rating and an $8 price target. However, technical indicators remain negative, suggesting continued volatility and caution for short-term investors.34

Anebulo Pharmaceuticals reported a reduced net loss of $2.5 million in its latest quarter, alongside a $15 million private placement to bolster cash reserves. The company is progressing with FDA discussions for its cannabis toxicity treatment, aiming to initiate a Phase 1 trial in the first half of 2025.56